Brilinta more effective than Clopidrogel, but with more side effects

Tuesday, August 13th, 2013

A recent study shows that clopidrogel was linked to certain outcomes but not survival after stenting. When combined with aspirin, it also had a poor response to dual antiplatelet therapy and a 2.49-fold greater risk of stent thrombosis, along with a 42 percent greater risk of heart attack. On the other hand, more potent agents […]

Dual Anti-platelet Therapy with Brilinta Useful after Coronary Stent Implantation

Thursday, July 18th, 2013

A recent review of medical literature on medical treatment following percutaneous coronary intervention (PCI) shows that a dual anti-platelet therapy using Brilinta may be a useful treatment option. PCI refers to stent placement, balloon angioplasty, and other procedures used to open up blocked or narrowed coronary arteries. A total of 91 studies were reviewed. The […]

Brilinta to Receive Funding Boost

Wednesday, July 17th, 2013

Ticagrelor (brand name Brilinta) is a blood thinning drug used to treat certain heart conditions. The medicine will received a funding boost of $14.3 million from Pharmac. Patients diagnosed with coronary artery obstruction or acute coronary syndrome will be able to access the ticagrelor anti-platelet therapy for 12 months without charge. During the first year, […]

Brilinta gets Funding in New Zealand

Friday, June 28th, 2013

Brilinta is the brand name for ticagrelor, and it is a new-generation blood thinner that has recently received funding for production in New Zealand. The medication is used for the treatment of acute coronary syndrome or ACS. Heart conditions like ACS are one of the leading causes of death in the country. Men have a […]